AMGN — Amgen Inc.
Healthcare · ETF XLV · as of 2026-09-18
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Amgen Inc.
NMS
Healthcare · Drug Manufacturers - General
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...
Price & today
$385.65
ATR(14) 10.00 (2.59%)
| Stock today | +1.55% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | +1.79% |
Sector correlation
| 20-day correlation with XLV | 0.80 |
| 60-day correlation with XLV | 0.72 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $390.53 |
| 20 EMA | $400.77 |
| 50 EMA | $397.39 |
| EMA stack | NEUTRAL |
| RSI(14) | 39.7 |
| 52-week high distance | -7.83% |
| 52-week low distance | +42.96% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | SELL (11d) |
| Sector rank | #474 |
| Next earnings | 2026-11-02 (AMC, 44d) |
MarketSmith metrics - our compute
RS Rating
17.4
ADR%
2.0
RMV (tight)
3.0
Ext (ATR>20EMA)
-1.5
Rel Vol
314.0%
U/D 50d
1.22
U/D 25d
1.03
Accum/Dist 25d
4 / 5
EPS YoY
+4.0%
LoD dist
71.0
Off 52w High
13.7%
Above 52w Low
43.0%
1W / 1M
+2.2 / -12.8
Avg $Vol 50d
1.08B
Mkt Cap (B)
208.1
Trend 8/8
no
Leads Group
no
Sector XLV
+1.8% 1W
Base len (VCP)
10wk (3/12)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
23.9
Fwd P/E
16.0
PEG
2.2
Price/Book
19.0
Profit margin
22.9%
ROE
91.5%
Debt/Equity
490.3
Rev growth
+9.5%
Analyst target
$378 (-2%)
Analyst rating
BUY
Institutional %
85.5%
Insider %
0.2%
Float %
98.8%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
4 / 147
Industry
Drug Manufacturers - General
Float
533.0M
Float turnover 20d
0.5%
Avg $Vol 20d / 50d
1.18B / 1.08B
Days to cover
4.7
Short % float
2.4%
Institutional %
85.5%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Oct-24 | 5.58 | +13% | 8,503.0 | +23% |
| Feb-25 | 5.31 | +13% | 9,086.0 | +11% |
| May-25 | 4.90 | +24% | 8,149.0 | +9% |
| Aug-25 | 6.02 | +21% | 9,179.0 | +9% |
| Nov-25 | 5.64 | +1% | 9,557.0 | +12% |
| Feb-26 | 5.29 | +0% | 9,866.0 | +9% |
| Apr-26 | 5.15 | +5% | 8,618.0 | +6% |
| Aug-26 | 6.29 | +4% | 10,054.0 | +10% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 18 · Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects? Zacks Investment Research
- Sep 17 · Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape GlobeNewswire Inc.
- Sep 16 · Should You Invest in the VanEck Biotech ETF (BBH)? Zacks Investment Research
- Sep 15 + 4 Defensive Stocks to Take Refuge in as Consumer Sentiment Plummets Zacks Investment Research
- Sep 15 + Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities GlobeNewswire Inc.
- Sep 14 + 4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike Zacks Investment Research
- Sep 11 + Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool
- Sep 11 + Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool